People who are suffering with fibromyalgia are very well familiar with the implications that their disease is less than genuine. But luckily, a lot of research has been made in this field now and researchers are working on finding more and more treatments for this disease. Recently, a new drug has been found and that has received a fast track status from FDA of US in treating fibromyalgia.
This drug is called IMC-1 and is a form of viral suppression. This drug has already completed its phase 2 proof of concept trials in a double-lined, placebo-controlled study successfully. The theory behind this IMC-1 is that maybe there is some relation of fibromyalgia with the herpes virus lying hidden in body tissue. The treatment of it is usually based on the potential effectiveness of different combination of viral suppression drugs that are used to suppress herpes.
This study was performed on 143 women from 12 clinics of U.S. all of these women were diagnosed with primary fibromyalgia in the past, using the criteria mentioned by 2010 College of Rheumatology. These women were evaluated for 16 week period periodically. Now, for going to the phase 3 trials, IMC is now working with FDA for meeting the requirements.
Researchers also observed that many of the symptoms of fibromyalgia are similar to the other diseases that are related with the herpes virus. Widespread chronic pain, sleep problems, mood problems and overwhelming fatigue are the most common and uncomfortable fibromyalgia symptoms. Frequent headaches, irritable bowel syndrome and cognitive issues like fibro fog are also found in many fibromyalgia sufferers.
Although, there are millions of Americans who are suffering from fibromyalgia until the researchers and scientific community has had few risk factors that cause this chronic condition. Because no blood test is available that can confirm the diagnosis of fibromyalgia and the options of getting it treated have also been limited. The reason why FDA has granted fast track to IMC-1 is the lack of effective treatments for fibromyalgia. Fast track designation encourages the development of the drug for the diseases that don’t have various treatment options.